63 results about "Sequential treatment" patented technology

A system allows for sequential treatment of sections of a zone. Access to each portion can be with a sliding sleeve that has a specific internal profile. Pump down plugs can be used that have a specific profile that will make a plug latch to a specific sleeve. Pressure on the plug when latched allows a sequential opening of sleeves while zones already affected that are below are isolated. The pump down plugs have a passage that is initially obstructed by a material that eventually disappears under anticipated well conditions. As a result, when all portions of a zone are handled a flow path is reestablished through the various latched plugs. The plugs can also be blown clear of a sliding sleeve after operating it and can feature a key that subsequently prevents rotation of the plug on its axis in the event is later needs milling out.

A system allows for sequential treatment of sections of a zone. Access to each portion can be with a sliding sleeve that has a specific internal profile. Pump down plugs can be used that have a specific profile that will make a plug latch to a specific sleeve. Pressure on the plug when latched allows a sequential opening of sleeves while zones already affected that are below are isolated. The pump down plugs have a passage that is initially obstructed by a material that eventually disappears under anticipated well conditions. As a result, when all portions of a zone are handled a flow path is reestablished through the various latched plugs. The plugs can also be blown clear of a sliding sleeve after operating it and can feature a key that subsequently prevents rotation of the plug on its axis in the event is later needs milling out.

An integrated treatment system using electrodialysis and pressure-driven membranes for deionizing and decontaminating liquids to a near-pure quality for use or reuse in industrial or municipal operations. The integrated system includes steps of pre-filtering contaminated feed liquids blending the filtered liquids in preparation for treating the mixed liquids in parallel or sequential treatment steps utilizing nanofiltration or reverse osmosis, proceeded by or followed by an integrated electrodialysis treatment. A control means selectively directs mixed liquids to each of the treatment units for treatment in parallel or in series depending on the conductivity and residual contaminants in the mixed liquids. In comparison with nanofiltration or reverse osmosis only systems, or electrodialysis only systems, the integrated system provides improved efficiencies for treatment, requires less energy to operate, and reduces maintenance and capital costs.

In one embodiment of the invention, a method comprises (a) implementing a first therapy in an implantable medical device (IMD) from a programmed sequence of therapies for a first time period, (b) implementing a second therapy from the sequence in the IMD for a second time period following the first time period, and repeating (a) and (b).

This invention relates to methods for providing cosmetic or other benefits to keratin-containing substrates by sequential treatment with cationically and anionically charged compounds, and compositions and kits containing them.

A coiled adaptive seat is held to a smaller diameter for delivery with a tool that can feature a locating lug for desired alignment of the seat with an intended groove in the inner wall of a tubular. The release tool retracts a cover from the seat allowing its diameter to increase as it enters a groove. Alternatively the adaptive seat is released near the groove and pushed axially in the string to the groove for fixation. Once in the groove the inside diameter of the string is a support for a blocking object so that sequential treatment of parts of a zone can be accomplished. The blocking object is removed with pressure, dissolving, milling or disintegration leaving a narrow ledge in the tubular bore from the seat that can simply be left in place or milled as well. An E4#10 from Baker Hughes is modified for adaptive seat delivery.

A coiled adaptive seat is held to a smaller diameter for delivery with a tool that can feature a locating lug for desired alignment of the seat with an intended groove in the inner wall of a tubular. The release tool retracts a cover from the seat allowing its diameter to increase as it enters a groove. Alternatively the adaptive seat is released near the groove and pushed axially in the string to the groove for fixation. Once in the groove the inside diameter of the string is a support for a blocking object so that sequential treatment of parts of a zone can be accomplished. The blocking object is removed with pressure, dissolving, milling or disintegration leaving a narrow ledge in the tubular bore from the seat that can simply be left in place or milled as well. An E4#10 from Baker Hughes is modified for adaptive seat delivery.

A containing catheter for facilitating sequential treatment operations therethrough, is provided. The containing catheter comprises a median portion comprising an elongated, substantially tubular member, and a distal portion, comprising a distal stiff member. A catheterization apparatus is provided, comprising the containing catheter and an elongated inner catheter insertable into the containing catheter. A method of catheterization is provided, comprising providing the containing catheter, stiffening a portion of the containing catheter and inserting the stiffened containing catheter into a body conduit of a patient.

The invention provides new application of galectin-4 protein in preparation of a huge liver cancer postoperative prognostic evaluation kit. Via wide and thorough researches, an inventor firstly discovers that detection of the relative expression level of the galectin-4 protein in a huge liver cancer tissue in an immunohistochemistry way can judge the risk of liver cancer recrudesce transfer of a huge liver cancer patient. The application has the main benefits as follows: the application of the galectin-4 protein in the preparation of the huge liver cancer postoperative prognostic evaluation kit, provided by the invention, points out that the galectin-4 protein can be used for preparing a protein molecular marker for prognosis of the huge liver cancer patient, and has important significance of guiding the huge liver cancer patient's postoperative monitoring and sequential treatment.

The present invention relates to the use of a combination comprising at least one host defense inducer and at least one biological control agent in a synergistically effective amount for controlling bacterial harmful organisms in useful plants. The biological control agent is selected from specific microorganisms and/or a mutant of these strains having all the identifying characteristics of the respective strain, and/or a metabolite produced by the respective strain. In a preferred aspect of the invention the host defense inducer is isotianil or a combination of isotianil and acibenzolar-S-methyl. The present invention also relates to a method for controlling bacterial harmful organisms in useful plants by treatment with a combination comprising at least one host defense inducer and at least one biological control agent in a synergistically effective amount. A further aspect of the present invention is directed to method for controlling bacterial harmful organisms in useful plants by subjecting the plants to be protected against attack by bacterial harmful organisms to two or more sequential treatment blocks.

Described herein are methods related to generating intermediate mesoderm (IM) cells, including using sequential treatment of small molecules and growth factors, and composition produced by the described methods. Using small molecules such as CHIR99021 in combination with FGF2 and RA, efficient differentiation of human pluripotent stem cells (hPSCs) into intermediate mesoderm, such as PAX2+LHX1+ cells, is achieved. The method is extensible different hPSC cell lines and does not require flow sorting. Importantly, resulting PAX2+LHX1+ cells, are capable of WT1 expression and addition of FGF9 and activin, PAX2+LHX1+ cells specifically differentiates cells into SIX2, SALL1, and WT1 expressing cells representative of cap mesenchyme nephron progenitor cells. The described methods and compositions facilitate and improve the directed differentiation of hPSCs into cells of the kidney lineage for the purposes of bioengineering kidney tissue and iPS cell disease modeling.

The present invention provides a method and a system that treats Neuromusculoskeletal conditions and/or injuries in an integrated and structured manner. Such conditions and/or injuries are not one-dimensional in origin, severity or persistence; they are multi-factorial. The present invention treats the conditions and/or injuries in a multi-disciplinary and structured sequence in order to maximize the efficacy of the treatment which results in a shorter period of treatment, fewer office visits and treatments, lower cost and increased patient satisfaction. More specifically, various embodiments of the present invention comprise a sequential treatment comprising transverse frictional massage, mobilization clearances, decreasing active stiffness and decreasing passive stiffness of the over-facilitated tissues, increasing active and passive stiffness of the inhibited tissues followed by neuromuscular re-education.

The invention relates to the technical field of biology, in particular to application of ICOSL (Inducible Costimulator Ligand) protein in preparation of a kit used for breast cancer prognosis evaluation. According to the invention, the immunohistochemistry technology and a semi-quantitative analysis method of a staining result are employed to analyze the expression level of the ICOSL protein in atumor tissue, and combine with post-operative follow-up information to determine whether the ICOSL protein expression has correlation with the prognosis of a breast cancer patient or not, wherein theICOSL protein can be used for preparing a protein molecular marker for determining the prognosis of the breast cancer patient to have important guiding significance for post-operative monitoring and sequential treatment of the breast cancer patients.

The invention relates to application of cyclin protein G1. Relative expression quantity of the cyclin protein G1 between tumor tissues and tissue adjacent to tumor is determined by utilizing an immunohistochemistry technology, picture taking by a microscope and computer image processing software, correlation between the relative expression quantity of the cyclin protein G1 and prognosis of postoperative patient with hepatocellular carcinoma is determined by combining postoperative follow-up visit information, the cyclin protein G1 can be applied to preparation of a protein molecule maker for judging the prognosis of the patient with liver cancer and has importance directive significance for postoperative monitoring and sequential treatment for patients with hepatocellular carcinoma.

The present invention relates to a hybrid anticancer prodrug simultaneously producing cinnamaldehyde and quinone methide. The hybrid anticancer prodrug according to the present invention sequentially releases quinone methide and cinnamaldehyde by H₂O₂ and acidic pH, and thus alkylates antioxidant GSH through the release of quinone methide, thereby inhibiting an antioxidative system and increasing oxidation stress, and generates and accumulates reactive oxygen species (ROS) through the release of cinnamaldehyde, thereby promoting apoptosis, and thus the hybrid anticancer prodrug according to the present invention can be favorably used as an anticancer drug by creating a synergetic anticancer effect through double stimulus-response and sequential treatment action in a cancer cell-specific manner.

The invention discloses application of CHKA proteins in preparing a kit for prognostic evaluation of liver cancer. The expression amount of the CHKA proteins in the tumor tissue is determined by means of an immunohistochemical technique, microscope photographs and computer image processing software. The method for determining the expression amount of the CHKA can be used for judging the prognosis effect of the postoperative liver cancer patient, and provides important guidance for the postoperative monitoring and the sequential treatment of liver cancer patients. Moreover, the invention further discloses a kit for the prognostic evaluation of liver cancer and the method.

The present invention is directed to the recovery of bacteria and microparasites, particularly Cryptosporidium and Giardia, from water samples by filtration through a mixed cellulose ester membrane, partial dissolution of said membrane with methanol followed by completion in the presence of acetone, and purification and concentration using glass beads as a secondary confinement matrix.

The invention relates to the technical field of a medicine preparation, and concretely discloses medicine for treating hypertension and a preparation method thereof. The medicine has the active ingredients of nifedipine and metoprolol, wherein the mass ratio of the nifedipine to the metoprolol is 2:1. The metoprolol can decelerate the heart rate and has the hypotensive effect; the nifedipine can accelerate the heart rate and has the hypotensive effect; the metoprolol and the nifedipine realize the mutual complementation, so that the hypotensive effect is enhanced; the contraindication, the intolerance and the side effects generated in the single medication process are reduced. Compared with the step treatment and sequential treatment of the single-ingredient medication, the composite medicine has the advantages that the taking and the treatment are simple, convenient and fast. Meanwhile, the medicine is applicable to about 90 percent of hypotensive people groups, and is particularly suitable for hyperdynamic and high-impedance hypertension; the myocardial ischemia due to hypertension can be obviously relieved; meanwhile, the atrioventricular hypertrophy and various conduction blocking can be delayed or blocked.

A coiled adaptive seat is held to a smaller diameter for delivery with a tool that features a locating lug for desired alignment of the seat with an intended groove in the inner wall of a tubular. The release tool retracts a cover from the seat allowing its diameter to increase as it enters a groove. Alternatively the adaptive seat is released near the groove and pushed axially in the string to the groove for fixation. Once in the groove the inside diameter of the string is a support for a blocking object so that sequential treatment of parts of a zone can be accomplished. The blocking object is removed with pressure, dissolving, milling or disintegration leaving a narrow ledge in the tubular bore from the seat that can simply be left in place or milled as well. An E4#10 from Baker Hughes is modified for adaptive seat delivery.